tuberculosis vaccine

5 June, 2024

Researcher Carlos Martín receives the Aragonese Prize of the Year

The professor leads the Mycobacteria Genetics team at the University of Zaragoza and the Aragon Health Research Institute (IIS Aragón), which develops the Aragonese vaccine against tuberculosis.
4 June, 2024

The potential of the tuberculosis vaccine against cancer

Researcher Nacho Aguiló from the University of Zaragoza, the Networked Biomedical Research Center for Respiratory Diseases (Ciberes) and the Aragón Health Research Institute (IIS Aragón), is working to demonstrate, together with his team, that these live vaccines are capable of reverse the effects of asthma and lung and bladder tumors.
20 February, 2024

The Aragonese vaccine against tuberculosis could reach the market in 2027 or 2028

Designed by the University of Zaragoza, with the professor of Microbiology and researcher at the IIS Aragón Carlos Martín at the helm, and developed by the Galician biopharmaceutical company Biofabri.